Inventor · disambiguated record
Jeremiah Degenhardt
Also filed as: DEGENHARDT JEREMIAH · DEGENHARDT JEREMIAH D · DEGENHARDT JEREMIAH DANIEL
1 granted patent·6 pending applications·0 citations·filing 2014–2023
14Inventor score
Files withONYX THERAPEUTICS INC3AMGEN INC1GILEAD SCIENCES INC1TAKEDA PHARMACEUTICAL COMPAMY LTD1TAKEDA PHARMACEUTICALS CO1
Top patents by PatentIndex Score
7 records- 0167US2023235406A1Immunoglobulin expression levels as biomarker for proteasome inhibitor responseONYX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 0260US2021238691A1Immunoglobulin expression levels as biomarker for proteasome inhibitor responseONYX THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 0358US2020354793A1Immunoglobulin Expression Levels as Biomarker for Proteasome Inhibitor ResponseAMGEN INC·Filed 2020·Application pending·0 cites
- 0457US2023340159A1Constrained conditionally activated binding proteinsTAKEDA PHARMACEUTICAL COMPAMY LTD·Filed 2023·Application pending·0 cites
- 0552US10870889B2Immunoglobulin expression levels as biomarker for proteasome inhibitor responseONYX THERAPEUTICS INC·Filed 2014·Granted Dec 22, 2020·0 cites·13 claims
- 0652US2024026011A1Constrained conditionally activated binding proteinsTAKEDA PHARMACEUTICALS CO·Filed 2021·Application pending·0 cites
- 0730US2017306050A1Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseasesGILEAD SCIENCES INC·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jeremiah Degenhardt files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →